Role of Neo-Sinus on Thrombogenicity of Aortic Valve Prostheses: Experimental Proof-of-Concept Study

新窦对主动脉瓣膜假体血栓形成性的影响:实验概念验证研究

阅读:1

Abstract

PURPOSE: Transcatheter aortic valve replacement (TAVR) is the standard treatment for patients with aortic diseases at high surgical risk. Transcatheter heart valve prostheses (THV) are inserted into the aortic valve, creating a new area between the native and artificial leaflets. This area, known as neo-sinus, increases the thrombogenicity of THVs. But there is a lack of testing methods that evaluate thrombogenicity in vitro. METHODS: To analyze the flow field within the native sinus and the neo-sinus, Particle Image Velocimetry (PIV) was performed with a thrombosis tester. Additionally, a comparative study was conducted with porcine blood on two polycarbonate urethane valves, with and without neo-sinus, respectively. Blood samples collected every hour were analyzed for platelet count, coagulation via ROTEM parameters, and plasma-free hemoglobin. Thrombus formation was detected optically. RESULTS: The PIV measurements yield a physiological flow field in the aortic root that were consistent with those reported in literature. The analyzed blood parameters reveal no obvious difference between the valve with neo-sinus and the valve without. A higher amount of thrombus material for the valve with neo-sinus was found. CONCLUSION: The visualized flow field shows low velocities and stagnation zones due to the presence of native leaflets. Clot formation at the heart valve prostheses are in accordance with in-vivo findings. The benchmark of the two valves indicates an increased thrombogenic potential due to the neo-sinus. The thrombosis tester simulates the natural environment after TAVR. Thereby, newly developed THVs can be evaluated in vitro and consequently optimized regarding their thrombogenicity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。